Advanced search    

Search: authors:"Henriette Mersebach"

6 papers found.
Use AND, OR, NOT, +word, -word, "long phrase", (parentheses) to fine-tune your search.

Efficacy and Safety of Once-Daily Insulin Degludec/Insulin Aspart versus Insulin Glargine (U100) for 52 Weeks in Insulin-Naïve Patients with Type 2 Diabetes: A Randomized Controlled Trial

Purpose The efficacy and safety of insulin degludec/insulin aspart (IDegAsp) once daily (OD) compared with insulin glargine U100 (IGlar) OD over 52 weeks in insulin-naïve adults with type 2 diabetes mellitus (T2DM) was investigated. Methods In this open-label, parallel-group treat-to-target trial, participants were randomized (1:1) to receive IDegAsp OD (breakfast, n = 266) or ...

Comparison of Insulin Degludec/Insulin Aspart and Biphasic Insulin Aspart 30 in Uncontrolled, Insulin-Treated Type 2 Diabetes: A Phase 3a, Randomized, Treat-to-Target Trial

-daily pre- or self-mixed insulin. Gregory R. Fulcher,1 Jens Sandahl Christiansen,2 Ganapathi Bantwal,3 Miroslawa Polaszewska Muszynska,4 Henriette Mersebach,5 Thomas H. Andersen,5 and Leo K. Niskanen,6

Elderly Patients with Diabetes Experience a Lower Rate of Nocturnal Hypoglycaemia with Insulin Degludec than with Insulin Glargine: A Meta-Analysis of Phase IIIa Trials

and Takeda. Henriette Mersebach and Thue Johansen are employed by and own stocks/shares in Novo Nordisk. Stephen Gough has received a research grant and travel costs from Novo Nordisk, and received

Insulin Degludec/Insulin Aspart Administered Once Daily at Any Meal, With Insulin Aspart at Other Meals Versus a Standard Basal-Bolus Regimen in Patients With Type 1 Diabetes: A 26-week, phase 3, randomized, open-label, treat-to-target trial

OBJECTIVE To evaluate efficacy and tolerability of a co-formulation of insulin degludec and insulin aspart (IDegAsp) with insulin aspart (IAsp) at other meals compared with basal-bolus therapy using insulin detemir (IDet) and IAsp.

A New-Generation Ultra-Long-Acting Basal Insulin With a Bolus Boost Compared With Insulin Glargine in Insulin-Naïve People With Type 2 Diabetes: A randomized, controlled trial

TIM HEISE CEES J. TACK ROBERT CUDDIHY JAIME DAVIDSON DIDIER GOUET ANDREAS LIEBL ENRIQUE ROMERO HENRIETTE MERSEBACH PATRIK DYKIEL MSC ROLF JORDE OBJECTIVE-Insulin degludec/insulin aspart (IDegAsp

Hypoglycemia in Type 1 Diabetic Pregnancy: Role of preconception insulin aspart treatment in a randomized study

SIMON HELLER PETER DAMM DMSC HENRIETTE MERSEBACH PHD TRINE VANG SKJTH RISTO KAAJA PHD MOSHE HOD SANTIAGO DUR AN-GARCA PHD DAVID MCCANCE ELISABETH R. MATHIESEN DMSC OBJECTIVE - A recent randomized